The discovery of the anti-viral APOBEC3 proteins is regarded as one of the most therapeutically promising breakthroughs in HIV/AIDS molecular virology in recent years. HIV pathogenesis depends on its accessory protein Vif, which functions to counteract the APOBEC3 proteins and trigger their degradation. Five APOBEC3 proteins are susceptible to Vif-mediated degradation, and all seven APOBEC3 proteins have been reported to be capable of individually suppressing the replication of Vif-deficient HIV. Given the additional capacity of these proteins to homo- and hetero-oligomerize, it is further possible that the APOBEC3 proteins form a combinatorial restriction network with a broader range of anti-viral activities exceeding those of individual proteins. Thus, this application has three major aims, each testing an innovative hypothesis that will positively impact the present state of the field. First, we will test the hypothesis that at least two of the understudied APOBEC3s contribute to HIV restriction in vivo. A combination of methods will be used to identify the minimal set of APOBEC3s required for restriction in non-permissive T-cell lines and pathogenesis-relevant primary CD4+ T lymphocytes including gene targeting, short hairpin RNA knock-downs, differentially APOBEC3-susceptible virus isolates, and novel APOBEC3 inhibitor compounds. We anticipate that these studies will enable us to show definitively which APOBEC3s contribute to HIV restriction. Second, we will directly test a combinatorial restriction hypothesis through systematic APOBEC3 co-expression, co- immunoprecipitation, co-encapsidation, single cycle, and spreading infection experiments. Third, we will use APOBEC3-null T-cell lines and DNA deaminase inhibitors as tools to quantify the contribution of the endogenous APOBEC3 proteins to the HIV mutation rate and spectrum. These studies are anticipated to have important implications for understanding virus evolution, immune evasion, and drug resistance. Taken together, this new knowledge will advance our fundamental understanding of the HIV-relevant human APOBEC3 repertoire and, importantly, help prioritize ongoing and future efforts to develop novel HIV/AIDS therapeutics that work by modulating this network.

Public Health Relevance

A detailed molecular definition of the human APOBEC3 proteins relevant to HIV restriction will facilitate the development of novel HIV/AIDS therapeutics that work by leveraging this critical innate immune defense system.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI064046-09
Application #
8604353
Study Section
Special Emphasis Panel (ZRG1-AARR-K (02))
Program Officer
Sharma, Opendra K
Project Start
2004-12-01
Project End
2015-01-31
Budget Start
2014-02-01
Budget End
2015-01-31
Support Year
9
Fiscal Year
2014
Total Cost
$327,598
Indirect Cost
$102,598
Name
University of Minnesota Twin Cities
Department
Biochemistry
Type
Schools of Medicine
DUNS #
555917996
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Refsland, Eric W; Hultquist, Judd F; Luengas, Elizabeth M et al. (2014) Natural polymorphisms in human APOBEC3H and HIV-1 Vif combine in primary T lymphocytes to affect viral G-to-A mutation levels and infectivity. PLoS Genet 10:e1004761
Albin, John S; Brown, William L; Harris, Reuben S (2014) Catalytic activity of APOBEC3F is required for efficient restriction of Vif-deficient human immunodeficiency virus. Virology 450-451:49-54
Matsui, Yusuke; Shindo, Keisuke; Nagata, Kayoko et al. (2014) Defining HIV-1 Vif residues that interact with CBF? by site-directed mutagenesis. Virology 449:82-7
Zhang, Wenyan; Wang, Hong; Li, Zhaolong et al. (2014) Cellular requirements for bovine immunodeficiency virus Vif-mediated inactivation of bovine APOBEC3 proteins. J Virol 88:12528-40
Land, Allison M; Shaban, Nadine M; Evans, Leah et al. (2014) APOBEC3F determinants of HIV-1 Vif sensitivity. J Virol 88:12923-7
Rathore, Anurag; Carpenter, Michael A; Demir, Ozlem et al. (2013) The local dinucleotide preference of APOBEC3G can be altered from 5'-CC to 5'-TC by a single amino acid substitution. J Mol Biol 425:4442-54
McDougle, Rebecca M; Hultquist, Judd F; Stabell, Alex C et al. (2013) D316 is critical for the enzymatic activity and HIV-1 restriction potential of human and rhesus APOBEC3B. Virology 441:31-9
Refsland, Eric W; Harris, Reuben S (2013) The APOBEC3 family of retroelement restriction factors. Curr Top Microbiol Immunol 371:1-27
Burns, Michael B; Lackey, Lela; Carpenter, Michael A et al. (2013) APOBEC3B is an enzymatic source of mutation in breast cancer. Nature 494:366-70
Land, Allison M; Law, Emily K; Carpenter, Michael A et al. (2013) Endogenous APOBEC3A DNA cytosine deaminase is cytoplasmic and nongenotoxic. J Biol Chem 288:17253-60

Showing the most recent 10 out of 38 publications